Day hospitals showed no clear difference in death or institutional care by the end of compared with alternative care or no care (low certainty).
Day hospitals showed no clear difference in deterioration in ADL in survivors compared with comprehensive care (low certainty).
Day hospitals showed no clear difference in death or deterioration in activities of daily living (ADL) compared with alternative care or no care (low certainty).
Day hospitals showed no clear difference in death or poor outcome (institutional care, disability or… compared with alternative care or no care (low certainty).
Day hospitals showed no clear difference in deterioration in ADL in survivors Various ADL measures compared with alternative care or no care (low certainty).
Day hospitals showed no clear difference in death by the end of compared with no comprehensive care (low certainty).
Day hospitals showed no clear difference in death or institutional care by the end of compared with no comprehensive care (low certainty).
Day hospitals showed no clear difference in death or deterioration in ADL compared with no comprehensive care (low certainty).
Day hospitals may leads to lower death or poor outcome (institutional care, disability or… compared with no comprehensive care (low certainty).
PPI triple therapy for 14 days probably leads to lower H. pylori persistence, regardless of regimen and dose compared with 7 days (moderate certainty).
PPI triple therapy for 10 days showed no clear difference in H. pylori persistence, PAN subgroup compared with 7 days (low certainty).
PPI triple therapy for 10 days may leads to lower H. pylori persistence, PAQ subgroup compared with 7 days (low certainty).
It is very uncertain whether PPI triple therapy for 10 days changes H. pylori persistence, PANi subgroup compared with 7 days (very low certainty).
PPI triple therapy for 10 days showed no clear difference in patients with adverse events, regardless of regimen and dose compared with 7 days (moderate certainty).
PPI triple therapy for 14 days probably leads to lower H.pylori persistence, regardless of regimen and dose compared with 10 days (moderate certainty).
PPI triple therapy for 14 days probably leads to lower H.pylori persistence, PCA subgroup compared with 10 days (moderate certainty).
PPI triple therapy for 14 days showed no clear difference in H.pylori persistence, PAN subgroup compared with 10 days (low certainty).
PPI triple therapy for 14 days showed no clear difference in patients with adverse events, regardless of regimen and dose compared with 10 days (low certainty).
PPI triple therapy for 14 days probably leads to lower H. pylori persistence, PCA subgroup compared with 7 days (moderate certainty).
PPI triple therapy for 14 days showed no clear difference in H. pylori persistence, PCN subgroup compared with 7 days (low certainty).